| Monotherapy |
N |
% |
Most frequently-prescribed drugs |
| Angiotensin-II receptor antagonists |
38 |
23.46 |
Losartan (13), Valsartan (8) |
| Calcium channel blockers |
32 |
19.75 |
Amlodipine (15), Diltiazem (8) |
| β-Adrenergic receptor antagonists |
31 |
19.14 |
Bisoprolol (13), Atenolol (8) |
| Angiotensin-converting enzyme inhibitors |
25 |
15.43 |
Enalapril (15) |
| Diuretics |
19 |
12.96 |
Loop diuretics: Furosemide (6), Torsemide (5);
Thiazides: Indapamide (5) |
| Other categories: Vasodilators, α-Adrenergic antagonists, Mixed adrenergic antagonists, Centrally-acting drugs |
15 |
9.26 |
Vasodilators: Minidoxil (1);
α-Adrenergic antagonists: Doxazosinmesylate (7);
Mixed adrenergic antagonists: Carvedilol (4); |
| Drug Combinations |
N |
% |
Most frequently-prescribed drugs |
| Angiotensin-II receptor antagonists + Diuretics |
29 |
61.70 |
Combinations with Hydrochlorothiazide:
Valsartan + Hydrochlorothiazide (9);
Irbesartan + Hydrochlorothiazide (6) |
| Angiotensin-converting enzyme inhibitors + Diuretics |
7 |
14.89 |
Enalapril + Hydrochlorothiazide (4) |
| Diuretic combinations |
5 |
10.64 |
Amiloride + Hydrochlorothiazide (4) |
| Calcium channel blockers + Angiotensin-II receptor antagonists |
2 |
4.26 |
|
| β-Adrenergic receptor antagonists + Diuretics |
2 |
4.26 |
|
| Calcium channel blockers +Statins |
1 |
2.13 |
|
| Calcium channel blockers + β-Adrenergic receptor antagonists |
1 |
2.13 |
|
